Market capitalization | $82.96b |
Enterprise Value | $102.01b |
PER (TTM) P/E ratio | 185.64 |
EV/FCF (TTM) EV/FCF | 12.91 |
EV/Sales (TTM) EV/Sales | 3.72 |
P/S ratio (TTM) P/S ratio | 3.03 |
P/B ratio (TTM) P/B ratio | 4.73 |
Dividend yield | 4.51% |
Last dividend (FY23) | $3.00 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
32 Analysts have issued a Gilead Sciences forecast:
32 Analysts have issued a Gilead Sciences forecast:
Dec '23 |
+/-
%
|
||
Revenue | 27,058 27,058 |
0%
0%
|
|
Gross Profit | 21,039 21,039 |
2%
2%
|
|
EBITDA | 12,437 12,437 |
3%
3%
|
EBIT (Operating Income) EBIT | 9,744 9,744 |
9%
9%
|
Net Profit | 5,664 5,664 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Head office | United States |
CEO | Daniel O'Day |
Employees | 18,000 |
Founded | 1987 |
Website | www.gilead.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.